kura stock guide: Kura Oncology (KURA)

A comprehensive, beginner‑friendly guide to kura stock (KURA), covering Kura Oncology’s business, pipeline, stock listing, financials, risks, governance and where to track and trade shares—updated ...

2024-07-12 08:51:00

By Ravi Clark

Article rating

4.3

118 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kura Oncology (KURA)

This page is a detailed, beginner‑friendly reference for kura stock, the publicly traded shares of Kura Oncology, Inc. It explains what the company does, key milestones in its corporate history, the clinical pipeline and collaborators, how kura stock is listed and traded, financial metrics and filings, analyst coverage and market sentiment, governance, risks common to biotech investors, and resources for up‑to‑date data. Readers will learn how to interpret common stock data for kura stock and where to find official, verifiable information.

As of 2026-01-27, according to Kura Oncology investor materials and public market data sources, the company remained a clinical‑stage biopharmaceutical firm focused on precision oncology. For the latest numeric values such as market capitalization and trading volume for kura stock, consult the company’s investor relations and exchange filings listed in the References and Data Sources section.

Company overview

Kura Oncology (ticker: KURA) is a Nasdaq‑listed, clinical‑stage biopharmaceutical company focused on small‑molecule therapeutics for oncology. The company’s stated mission is to develop precision medicines that address defined molecular subsets of cancer. Headquartered in the United States, Kura Oncology pursues a business model centered on in‑house drug discovery and development, coupled with selective collaboration and licensing agreements to advance and commercialize leading candidates.

Kura Oncology positions itself as a precision oncology firm that discovers, develops and aims to commercialize therapies targeted at genetically defined patient populations. For investors evaluating kura stock, the company’s pipeline progress, regulatory milestones and financing posture are typically the primary stock drivers.

Corporate history

Kura Oncology’s corporate history includes its founding, early discovery work, clinical program launches and capital markets activities that led to public listing and subsequent financings. Key historical themes to track when researching kura stock include:

Founding and early research focus on small‑molecule oncology agents and target identification.
Advancement of lead programs into human clinical trials.
Strategic collaborations and licensing deals with pharmaceutical partners to expand development capacity or commercial reach.
Equity financings, convertible notes or other capital raises that affect shares outstanding and dilution for kura stockholders.
Public listing events, such as the initial public offering (IPO) and dates of Nasdaq listing under the ticker KURA.

Significant milestones—such as first‑in‑human studies, regulatory designations (e.g., Breakthrough Therapy or Fast Track), positive pivotal data, or approvals—have historically produced the largest single‑day moves in kura stock price. When assessing the company’s history, verify milestone dates and descriptions against company press releases and SEC filings.

Pipeline and products

Kura Oncology is a clinical‑stage company; its enterprise value and investor interest are tied closely to the status of its research and development programs. The following summarizes principal programs commonly associated with Kura as of recent company disclosures and industry reporting.

Ziftomenib (often referenced under brand or investigational names in company materials): a lead small‑molecule inhibitor developed for defined genetic subsets of acute myeloid leukemia (AML) and related malignancies. Clinical development stage: clinical trials (see company disclosures for up‑to‑date phase status and indications). Collaborations and licensing terms, if any, are reported in company announcements.
Tipifarnib: a farnesyltransferase inhibitor with development history in oncology indications; development stage and specific programs should be confirmed in Kura’s pipeline updates.
KO series candidates (for example KO‑2806, KO‑947, KO‑539 in various program descriptions): investigational molecules targeting epigenetic regulators or signaling pathways relevant to oncology. Development stages range from preclinical to clinical for different molecules.
Combination studies and biomarker‑driven trials: Kura often evaluates novel agents in combination with other therapies or in genetically selected patient populations, a common practice in precision oncology development.

For every program above, it is critical for investors and readers to consult the latest company press releases, clinicaltrials.gov entries and SEC filings for accurate, time‑stamped information on indication, trial phase, enrollment status, trial endpoints and any regulatory designations. Pipeline success or failure materially affects kura stock valuation.

Stock information

This section explains how kuru stock is represented in public markets and which metrics investors commonly monitor when tracking Kura Oncology shares.

Kura stock trades under the ticker symbol KURA on the Nasdaq stock exchange. Standard stock‑related data to monitor for kura stock include real‑time price, market capitalization, shares outstanding, 52‑week high/low, average daily trading volume, and typical trading hours. For authoritative, up‑to‑date figures, consult the company’s investor relations page, SEC filings (e.g., Form 10‑Q, 10‑K) and the Nasdaq feed.

Trading symbols and listings

Primary listing: Nasdaq — ticker symbol: KURA.
As of the latest public disclosures, Kura Oncology does not have widely traded ADRs or secondary global exchange listings. Confirm current listings on the company IR site and exchange notices, as corporate actions can introduce other listings.

When searching for kura stock, ensure you select the correct ticker (KURA) and confirm the exchange to avoid confusion with other entities using the word "Kura." The Related Companies and Name Disambiguation section later in this article highlights other public companies with similar names.

Historical price performance

Historical price charts for kura stock are essential for understanding volatility and the relationship between company news and share price moves. Key considerations when examining historical performance:

Breakpoints: identify dates of major press releases (clinical trial readouts, regulatory decisions, collaboration announcements, or financing notices) and observe corresponding price moves.
Volatility: clinical‑stage biotechs like Kura often experience above‑average intraday and longer‑term volatility tied to binary clinical outcomes.
Timeframes: examine short‑term (1‑3 months), medium‑term (6‑12 months) and long‑term (multiple years) charts to understand trend context for kura stock.

When presenting historical share price trends for kura stock, it is standard to show price series, volume overlays and annotated events. Public data providers and the company’s charting tools provide historical data windows and interactive charts.

Financials and key metrics

For kura stock, financial statements and key metrics reveal the company’s runway, spending profile and balance sheet health—critical given the cash‑intensive nature of clinical development. The items investors typically review include:

Revenue: clinical‑stage companies may report limited or no product revenue; revenue may come from licensing, milestone payments or collaboration income.
Research & development (R&D) expense: measure of cash burned to advance clinical programs.
Selling, general & administrative (SG&A) expense: corporate overhead and commercialization preparedness costs.
Net income/loss and operating cash flow: indicate whether operations are cash‑consuming.
Cash, cash equivalents and marketable securities: the company’s liquidity position and expected runway.
Debt and convertible instruments: obligations that can affect capitalization and dilution.
Shares outstanding and basic/diluted share counts: used to compute per‑share metrics for kura stock.
Key ratios where applicable: price/sales, enterprise value to cash runway, and other biotech‑appropriate metrics. Earnings multiples like P/E are often not meaningful for clinical‑stage companies that report net losses.

Quarterly (Form 10‑Q) and annual (Form 10‑K) reports provide these figures with standardized footnotes. When writing about kura stock, cite the reporting period for each financial item (for example: "As of the quarter ended September 30, 2025, Kura reported X cash and equivalents, per its Form 10‑Q").

Investor relations and filings

Kura Oncology’s investor relations (IR) site is the primary source for official materials referencing kura stock. Typical IR resources include:

Press releases and news archives documenting clinical updates, regulatory events and corporate actions.
SEC filings: Forms 8‑K for material events, 10‑Q for quarterly results, 10‑K for annual reports, and DEF 14A for proxy statements.
Presentations, investor slide decks and webcasts for earnings calls or R&D updates.
Contact information for investor relations and scheduled investor events (e.g., R&D day, annual shareholder meeting).

As of the latest disclosures, investors should check the IR page and SEC EDGAR filings for time‑stamped documents that are the authoritative record for any claims about kura stock performance, equity structure or corporate obligations.

Analyst coverage and market sentiment

Analyst coverage, consensus price targets and institutional ownership can shape market sentiment around kura stock. Common points to review:

Coverage: which sell‑side analysts publish research notes and how frequently.
Consensus price targets: aggregated analyst views on fair value (note: analyst opinions vary and change with clinical data).
Rating distribution: buy/hold/sell opinions (if available) and the rationale behind each.
Institutional ownership: the percentage of shares held by mutual funds, hedge funds and other institutional investors; changes in institutional positions can influence liquidity and stock behavior.
Retail and social sentiment: trading activity and discussion on retail platforms and message boards may contribute to short‑term volatility in kura stock.

When reporting analyst views and market sentiment, always attribute sources and reporting dates, and avoid presenting opinions as facts.

Commercial and regulatory milestones

For kura stock, regulatory milestones and any first commercial sales are pivotal events. Areas to monitor:

Regulatory filings and approvals: Investigational New Drug (IND) filings, Biologics License Applications (BLAs) or New Drug Applications (NDAs), Fast Track/Breakthrough/Orphan designations.
Pivotal trial readouts and approval decisions: positive or negative results materially affect kura stock.
Launches and first commercial revenues: if and when a program moves to commercial sales, this marks a transition in the company’s revenue profile.
Label changes, safety updates and post‑marketing commitments: these can impact usage and reimbursement.

All regulatory and commercial milestone statements should cite the date and source (e.g., company press release, regulatory agency notice). For example: "As of [date], according to Kura Oncology’s press release dated [date], the company reported [milestone]." This format ensures readers can verify the statement.

Risks and considerations

Investors interested in kura stock should be aware of typical biotech and biopharma risks. Common categories include:

Clinical trial risk: the possibility that a trial fails to meet endpoints or encounters safety issues.
Regulatory risk: uncertainty in approval pathways, differing agency requirements and potential delays.
Funding and dilution risk: clinical development is capital‑intensive; additional equity raises or convertible securities issuance can dilute existing kura stockholders.
Commercialization risk: even after approval, there are uncertainties regarding pricing, reimbursement, market uptake and competition.
Intellectual property and competition: patent life, freedom‑to‑operate and competitive entrants in the same therapeutic space matter for long‑term value.
Market volatility: biotech stocks often exhibit amplified reactions to news and sentiment shifts.

This is not an exhaustive list and is intended to help readers understand the primary risk vectors that most affect kura stock performance. All readers should consult the company’s Management Discussion & Analysis and Risk Factors in Form 10‑K/10‑Q for a detailed statement of risks.

Corporate governance and management

Corporate leadership and governance practices influence investor confidence in kura stock. When evaluating management, consider:

Executive leadership: CEO, CFO and heads of R&D who shape strategy and execution.
Board composition: directors’ industry experience, independence and relevant expertise.
Insider transactions: buying or selling by executives and directors can be informative, though not determinative, about insider views.
Compensation policies and alignment with long‑term shareholder interests.

For kura stock, pay attention to leadership changes, executive departures or additions, and any governance matters disclosed in proxy statements. These items are reported in DEF 14A filings and company press releases.

Related companies and name disambiguation

The term "Kura" appears in the names of multiple public companies. To avoid confusion when researching kura stock, note the following distinctions:

Kura Oncology (ticker: KURA) — Nasdaq‑listed biopharmaceutical company focused on oncology.
Kura Sushi USA (ticker differs) — a food/restaurant company and a separate public entity (not affiliated with Kura Oncology).

When searching for kura stock by ticker or company name, confirm the ticker symbol (KURA) and the sector (biopharma/biotech) to ensure you are viewing the intended issuer’s data.

References and data sources

For reliable, verifiable information on kura stock, use primary and reputable secondary sources. Commonly used authoritative sources include:

Kura Oncology investor relations materials and press releases (official announcements and presentations).
U.S. Securities and Exchange Commission (SEC) filings, including Form 10‑Q, Form 10‑K, Form 8‑K and proxy statements.
Nasdaq exchange data and official ticker listings for KURA.
Reputable financial data providers for stock price history, volume and market capitalization.
Clinical trial registries (e.g., clinicaltrials.gov) for study protocols and status.

As of 2026-01-27, according to Kura Oncology’s public filings and Nasdaq announcements, investors should rely on those primary sources for any time‑sensitive claims about kura stock performance or corporate events.

Frequently asked questions (FAQ)

Q: What is the ticker symbol for kura stock? A: The ticker symbol is KURA and the primary exchange listing is Nasdaq.

Q: Is Kura Oncology a commercial company with product revenue? A: Kura Oncology has been primarily a clinical‑stage company; revenue may be limited to collaboration income or milestone receipts until any potential product approvals and commercial launches are achieved. Check the latest Form 10‑Q or press release for current revenue status.

Q: Where can I find the latest pipeline updates that matter for kura stock? A: Official press releases on Kura Oncology’s investor relations page and clinicaltrials.gov entries for specific studies are the most reliable sources for trial status and program descriptions.

Q: Are there other public companies with the name "Kura"? A: Yes. For example, restaurant or consumer businesses use the name Kura; confirm the ticker and sector to avoid confusion with kura stock (KURA) which is Kura Oncology.

Notes on sources and reporting dates

As of 2026-01-27, authoritative information about Kura Oncology’s pipeline, financials and corporate events is available in the company’s investor relations materials and SEC filings. Any quantitative figure cited in this article should be cross‑checked with the source document and its reporting date.
Example citation format to use when verifying a specific datum: "As of [date], according to Kura Oncology’s Form 10‑Q filed on [filing date], the company reported $[amount] in cash and equivalents." Use the filing date and exact figure from the document when citing.

Final notes and next steps

kura stock is representative of the broader dynamics affecting clinical‑stage biotech equities: high information sensitivity, event‑driven volatility and the centrality of trial and regulatory milestones. This article provided a structured reference for company background, pipeline, listing details, financial metrics, investor resources and risk considerations.

Further exploration: for real‑time quotes, historical charts and up‑to‑date filings about kura stock, consult Kura Oncology’s investor relations and official SEC filings. To execute trades or manage multi‑asset exposure, consider Bitget’s trading services and Bitget Wallet for custody needs.

Explore more company materials and stay current with primary filings to verify any material claims about kura stock.

Disclaimer: This article is informational and educational only. It is not financial, investment or legal advice. All readers should verify facts and consult licensed professionals before making investment decisions. Company events and numbers change over time—always refer to the primary source documents cited in the References and Data Sources section.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.